Recently, the "2023 China Brand Value Evaluation Information" was released by Xinhua News Agency in conjunction with the China Brand Building Promotion Association, the China Asset Evaluation Association, and other units. Jiangsu Hansoh Pharma, the core subsidiary of Hansoh Pharma, has risen to second place for Pharmaceuticals brands in China with a brand strength of 903 and a brand value of 27.608 billion RMB, reaching a new high.
The brand strength index highlights the core competitiveness of a company's brand, while the brand value reflects the overall strength of a company. The sustained growth of Jiangsu Hansoh Pharma's brand strength and brand value over the years fully demonstrates the remarkable results of its high-quality innovative development.
As a leading innovation-driven pharmaceutical company in China, Hansoh Pharma has implemented its own extensive brand-strengthening strategy as it has strived to continuously enhance technological innovation and intellectual property protection, and has made continuous breakthroughs in areas such as new drug research and development, quality management, marketing services, and ESG. Up until now, the company has successfully marketed six innovative drugs, all of which are included in the national reimbursement drug list (NRDL). It also has more than 40 clinical trials being conducted for over 30 innovative drug projects, thereby retaining a rich pipeline to continuously improve the well-being of the people.
Technological innovation focuses on patient needs, while brand leadership drives value growth. Hansoh Pharma will adhere to the goal of meeting patient needs, continuing to develop more new high-quality drugs, and contributing to the global outreach of Chinese brands.
About the Release of China's Brand Value Evaluation Information
China's Brand Value Evaluation Information has been released for the past 10 years. It follows national and international standards, adheres to the principles of being "scientific, fair, open, and acknowledged", and selects industry leaders as benchmarks. It has become an important measure to establish a brand value evaluation mechanism with Chinese characteristics, create positive energy for Chinese brands, and promote Chinese brands to the world.
About Hansoh Pharma
Hansoh Pharma is a leading innovation-driven pharmaceutical company in China. It focuses on major disease treatment areas including oncology, anti-infectives,CNS diseases and metabolic diseases as well as autoimmune diseases ，and is dedicated to improving human health through continuous innovation. As of now, the company has marketed six innovative drugs, forming a rich product pipeline. It has continued to maintain its position among the top 100 global pharmaceutical companies and the top three best industrial companies for the pharmaceutical R&D product line in China for a number of consecutive years. It is a National Key High-Tech Enterprise and a National Model Enterprise in Technological Innovation. The company was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 3692.HK).
